management of these patients to prevent nephronal loss and endstage renal disease.
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for advanced malignant and select benign hematopoietic disorders. Chronic GVHD (cGVHD) develops in 50-80% of recipients and remains a major cause of post-HCT morbidity and mortality. 1, 2 The development of acute and chronic renal insufficiency has been increasingly recognized as a complication of allo-HCT. Renal disease can be seen early or late after allo-HCT and has many potential etiologies but renal dysfunction as a consequence of cGVHD is uncommon. Murine models support an etiologic relationship between GVHD and the development of renal disease. Injection of DBA/2 donor murine lymphocytes into F1 hybrid mice produces a murine model of GVHD associated with heavy proteinuria. 3 Clinical case reports and case series have documented nephrotic range proteinuria (NRP) after allo-HCT in humans. 4 We conducted a retrospective study in all patients who underwent allo-HCT between 2005 and 2011 at our institution and subsequently developed NRP. NRP was defined as presence of ⩾ 3 g of protein in a 24 h urine specimen (Brenner's and Rector's, The Kidney, 9th edition). It is our institutional policy to screen allo-HCT recipients for development of NRP with 24 h urine protein if they develop unexplained peripheral edema, generalized swelling, hypoalbuminemia or decrease in renal function. All patients included in this report received uniform acute GVHD prophylaxis with MTX and tacrolimus.
All patients who developed NRP underwent a renal biopsy. Renal biopsies were processed in the usual manner and the biopsy specimens were reviewed for histopathology and EM by an expert nephropathologist.
To assess response to therapy, CR of NRP was defined as a 24-h urinary protein level ⩽ 0.5 g/dL, serum albumin levels ⩾ 3.5 g/dL, and achievement of stable renal function. 5 PR was defined as reduction in 24-h urinary protein by at least 50% from baseline or below 2.5 g/24 h with serum albumin levels ⩾ 3 g/dL and stable renal function. 5 Between 2005 and 2011, 271 adult patients underwent allo-HCT at our institution. Nine patients (3.3%) in this cohort developed NRP and were included in the analysis. Table 1 shows baseline characteristics and outcomes of these patients. The median age at the time of transplantation was 51 years (range 42-64 years). Four patients underwent matched unrelated donors transplantation, whereas five received matched sibling donor (MRD) allografts. Six patients received myeloablative conditioning before allo-HCT. Peripheral blood was the graft source in all patients. None of the patients had a prior history of NRP, abnormal renal function or any evidence of disease relapse before the onset of proteinuria.
The onset of NRP in our cohort was a late event, occurring at a median of 812 days after transplantation (range 342-2555 days). The amount of proteinuria ranged from 3.3 to 10.2 g in 24 h urine specimens. Serum albumin level ranged from 2.2 to 3.7 g/dL with a median value of 3 g/dL. As shown in Table 1 , seven patients had a preceding history of cGVHD. Among these seven patients, three were off immunosuppression, one was being tapered off immunosuppression and the remaining two patients were on active immunosuppression for cGVHD. In the remaining two patients NRP was the sole (potential) manifestation of cGVHD.
On histological and electron microscopic evaluation, four patients had membranous glomerulonephritis (MGN) (Figure 1a) . One patient had minimal change disease (MCD) with evidence of effacement of foot processes (Figure 1b) . Two patients had focal segmental glomerulosclerosis and two patients had histological changes consistent with tubulitis and interstitial inflammation. There was no evidence of hepatitis B and hepatitis C in any patients and antinuclear Ab panel was negative in all these patients.
As shown in Table 1 , all patients were started on corticosteroids. Three patients required combination therapy with tacrolimus and prednisone to achieve CR of proteinuria (time to CR 20 days, 30 days and 54 days, respectively). One patient had CR with prednisone (within a week) but later on had multiple recurrences, but responded to prednisone with PR at each subsequent episode. One patient did not respond to treatment with prednisone and mycophenolate mofetil. The remaining three patients required various combinations of immunosuppression including prednisone, mycophenolate mofetil, tacrolimus, sirolimus and rituximab. Two of these patients had CR (time to CR range from 37 to 1400 days) whereas the remaining one had PR. One patient who did not respond to immunosuppression (prednisone and mycophenolate mofetil) went on to develop end-stage renal disease and required hemodialysis. Relapse of NRP occurred in four patients. Among these four relapsing patients, two patients relapsed after having achieved a CR, but later required combination of immunosuppression to achieve another PR. Remaining two patients had PR before the relapse, one patient responded to the same agent (prednisone) and the other required combination of agents and continued to remain in PR. At the time of last followup, five of nine patients were alive, one died from septic shock whereas the other two died of infectious complications in the setting of active GVHD.
Development of NRP associated with cGVHD secondary to immune-mediated glomerular damage is a rare event. Our series suggests that NRP was a late event, but responsive to immunosuppressive therapy. The histologies included in our cohort are more diverse than previously reported.
6-8 Tubulitis histology has not been reported before in this setting. NRP occurred only in recipients of peripheral blood allografts, suggesting that the risk of NRP may be higher with this graft source.
Reddy et al. 6 observed an overall incidence of 1% (9 of 889 patients) in their cohort with two patients in their study having developing NRP without evidence of cGVHD. Luo et al. 7 reported a 5-year cumulative incidence of NRP of 3.5% with cGVHD present in eight of nine cases. In both of these series, MGN was the most common histopathology. Post allo-HCT nephrotic syndrome tends to occur after cessation or tapering of immunosuppression.
A review of literature by Brukamp et al. showed that of those patients who developed nephrotic syndrome, 61% have membranous nephropathy and 22% of have MCD. 9 The predominant underlying hematologic diagnosis was CML, whereas AML and aplastic anemia were other common diagnoses. cGVHD, immunosuppression withdrawal and peripheral stem cell graft have previously been reported as risk factors for membranous glomerulopathy post allo-HCT. 10 The association between post-allo-HCT NRP and GVHD is intriguing. In the experimental models of cGVHD, evidence of B-cell dysregulation is well described. [11] [12] [13] The kidney is a rare target organ in cGVHD, but the development of renal disease after allo-HCT occurring temporally with cGVHD suggests that the renal tubular system might be a potential cGVHD target. Resolution of proteinuria with anti-CD20 Ab in our and other series support the role of B-cell dysregulation in renal pathology as in other manifestations of cGVHD. 6, 14 In summary, our series indicates that NRP can be a manifestation of cGVHD. Beyond MGN and MCD, other histologies known to cause NRP are also possible in the post allo-HCT setting. We recommend that the patients should be evaluated for NRP at 6 months, 1 year and then annually for NRP. 15 For responding patients immunosuppression should be tapered off quickly to decrease the risk of immunosuppression. Timely recognition of this uncommon cGVHD manifestation is necessary in the Abbreviations: Cy = cytoxan; Flu = fludarabine; FSGS = focal segmental glomerulosclerosis; MA = myeloablative; MCD = minimal change disease; MGN = membranous glomerulonephritis; MM = multiple myeloma; MMF = mycophenalate mofetil; MRD = matched related donor; MUD = matched unrelated donor; NA = not applicable; NHL = non-Hodgkin's lymphoma; NR = no response; PDN = prednisone; RIC = reduced intensity; RTX = rituximab; Siro = sirolimus; TAC = tacrolimus. 
